Every new front-door diagnostic reshapes downstream echo demand. It's the referral threshold the GP adopts that matters. Lower it too far and you've bought a waiting list, not better outcomes.

73,701 reports and no device problem found. Genuinely wonder how many are "we don't know" masquerading as "nothing wrong." #HeartFailure #ClinicalValidation #Diagnostics

to be fair that 94% reduction in inconclusive ECGs is a good headline. But if the reference standard was cardiologist adjudication of those same traces, you've built a device that performs well against the judgment calls it was trained on. Worth interrogating before procurement.

Class II recall on a Tuesday. Could be worse, I suppose.

CE mark not a green light - QMS must enforce clinical eval, PMS/UDI & heed MAUDE signal #4 before wide autonomous breast-screen rollout.

A vendor's evidence page can be accurate and still leave the commissioning question unanswered. I look for the full paper, intended population, comparator and patient-level outcome. An AUROC in a selected cohort is a long way from fewer admissions across 1.4m residents. What do you check first?

510(k) faster; de novo for genuinely new AI.

A model validated in 2019 has no automatic claim on 2026 safety. Coding practice, referral thresholds and disease prevalence move; calibration can quietly go stale while AUROC looks respectable. Before renewal, I want site-level performance by age, sex and deprivation, plus a stop rule.

69,424 MAUDE reports Apr-Aug with no identified device problem, alarming; underfunded mean hospitals (and taxpayers) pay later. #HeartFailure #Diagnostics #HealthInequality

before an AI-ECG pilot, ask what happens to false negatives. A headline AUROC won't tell you whether women, older patients or people with intermittent AF are missed. Require subgroup sensitivity, clinician override rates and cost per actionable case. In fairness, accuracy is half the pathway.

Algorithm first-pass, GP for most, cardiologist for the tricky cases, like Leeds, one backs grit.

The procurement question I wuold add: what happens after the algorithm reads the ECG first? In fairness, a good flag can shorten the pathway. But anchoring means rare patterns become missed patterns. Keep a human read in training, audit overrides, and price deskilling into the pathway.

PGDx PMA (Class III), QMS won't sleep...

A normal resting echo can coexist with exertional HFpEF. In my experience, breathlessness is too often filed as deconditioning before anyone asks what happens on stairs. Symptoms should trigger the next diagnostic step, not end the pathway. That is where pathway design matters.

Good tech needs proper training - or it's just expensive shelfware.

Before piloting an AI ECG tool, ask where false positives land. An AF flag may prevent stroke, while generating anticoagulation reviews, echoes and clinic demand. In fairness, upside may be substantial. I want PPV by age, sex and ethnicity, plus an owner for each alert. What belongs?

AF screening is often framed as opportunistic checks versus a systematic programme. The harder question comes after the irregular pulse: who confirms it, starts anticoagulation, and owns follow-up? Detection without a pathway is theatre. In fairness, opportunistic checks may be the sensible start.

Brevera with CorLumina trending, looks handy for speeding biopsies. Device cost is real; at ICB scale one needs uptake across ~6-8 sites before pathway savings actually show.

a differential diagnosis without an owner and review date is paperwork with better vocabulary. In fairness, uncertainty is often unavoidable. The failure is leaving it unstructured: what would change the working diagnosis, who checks, and when. That is how a £14k admission becomes 'unexpected'.

Phonocardiography is having a quiet comeback. The QMS question is whether a changed sensor, adhesive or noise-filtering algorithm triggers verification, usability work and a risk-file update. 'Equivalent' hardware can alter the signal. A closed CAPA proves little without an effectiveness check.

The costly miss in older people is upstream: breathlessness gets filed under 'age' or COPD, while aortic stenosis waits. NICE recommends specialist assessment for suspected valve disease:. Earlier listening may prevent an expensive admission. https://www.nice.org.uk/guidance/ng208

gORE VIABIL recall: 7cm with transmural holes mislabelled as 10cm, classic design-control/labeling failure (21 CFR 820.30). Urgent CAPA, inventory hold and trace to clinical sites needed.

the useful Italian lesson is the pathway: a screening ECG is the front door. An abnormal trace triggers expert review and echocardiography, linking an electrical clue to cardiomyopathy. In fairness, that adds false positives and cost. ECG-only programmes borrow the test and forget the plumbing.

A machine may flag a murmur. A clinician can hear its timing, radiation and response to position. Add exertional breathlessness and the sensible next step is an echo pathway, not reassurance from a score. In fairness, digital tools may widen access. They cannot supply the clinical context.

Herzschwäche: Wer profitiert von Telemedizin? Erfolg der Fernbetreuung hängt stark von Lebenssituation & Geschlecht ab Eine neue Analyse der E-INH-Studie des Deutschen Zentrums für Herzinsuffizienz (DZHI) Würzburg zeigt, dass eine Fernbetre... weiterlesen

A one-clinic cardiac diagnostic pilot should measure the queue it creates, not just its accuracy. Track time from test to treatment, false positives, missed cases, referrals avoided, uptake by deprivation/sex/age, and 90-day admissions. A £14k HF admission makes pathway follow-through the real test.

allura Xper FD Class II recall (722026-722038): firmware geometry loss = design-control gap; insist on CAPA log, FSN & site mapping. #PrimaryCare #Diagnostics #ClinicalValidation

an echo waiting list can turn breathlessness into postcode medicine. The patient labelled 'deconditioned' waits; the one who reaches hospital gets an echo, a diagnosis and a treatment plan. In fairness, demand is real. Access is deciding who gets diagnosed...

A diagnostic model's heatmap can reassure while calibration fails by age, sex or referral setting. Clinicians need failure boundaries, an override route and monitoring that reflects the local pathway. In fairness, explanations help training. They do not validate a model or find missed HFpEF alone.

Class III recall (SMN 10445390), Syva Emit Tox TCA calibrator Lot U2: sodium azide out of spec. In fairness, one dodgy lot can skew TCA results and risk harm; labs need urgent contingency and clinicians should treat results cautiously. #ClinicalValidation #Diagnostics #PrimaryCare